Molecure S.A. (MOC.WA)
Warsaw · PLN · Healthcare · Biotechnology
PLN 6.08 (+1.67%) as of
Key statistics
- Market cap
- 150.32M
- Forward P/E
- -60.80
- EPS (TTM)
- -0.94
- Dividend yield
- 0.00%
- 52-week range
- 4.98 – 9.04
- Beta
- 1.00
- Revenue (TTM)
- 6.52M
- Profit margin
- -240.64%
- Analyst target
- PLN 13.10
- Volume
- 26.71k
About Molecure S.A.
Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-40 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022. Molecure S.A. was founded in 2012 and is headquartered in Warsaw, Poland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Warsaw, Poland
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.